Regulatory Approvals

Recon: New FDA oncology chief vows continued innovation in OCE; FDA approves drugs for two rare genetic diseases

By

Regulatory Approvals — Recon: New FDA oncology chief vows continued innovation in OCE; FDA approves drugs for two rare genetic diseases  RAPS

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 14, 2026.

By

Related Post

Regulatory Approvals

FDA Approves TLX101-Px for Glioma Imaging

Regulatory Approvals

FDA Approves Aminolevulinic Acid Gel With PDT for Superficial Basal Cell Carcinoma

Regulatory Approvals

FDA Approves Topical Photodynamic Therapy for Superficial BCC

Financial News For All

Labor

Oracle begins a new round of layoffs. Read the email.

Regulatory Approvals

Recon: New FDA oncology chief vows continued innovation in OCE; FDA approves drugs for two rare genetic diseases

Regulatory Approvals

FDA Approves Topical Photodynamic Therapy for Superficial BCC

Regulatory Approvals

FDA Approves Aminolevulinic Acid Gel With PDT for Superficial Basal Cell Carcinoma